Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma

被引:12
|
作者
Alfaifi, Abdullah [1 ,2 ]
Refai, Mohammed Y. [3 ]
Alsaadi, Mohammed [1 ,4 ]
Bahashwan, Salem [4 ,5 ,6 ]
Malhan, Hafiz [7 ]
Al-Kahiry, Waiel [7 ]
Dammag, Enas [7 ]
Ageel, Ageel [7 ]
Mahzary, Amjed [8 ]
Albiheyri, Raed [1 ]
Almehdar, Hussein [1 ]
Qadri, Ishtiaq [1 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia
[2] Minist Hlth, Fayfa Gen Hosp, Jazan 83581, Saudi Arabia
[3] Univ Jeddah, Coll Sci, Dept Biochem, Jeddah 21493, Saudi Arabia
[4] King Abdulaziz Univ, King Fahad Med Res Ctr, Hematol Res Unit, Jeddah 21589, Saudi Arabia
[5] King Abdulaziz Univ, Fac Med, Dept Hematol, Jeddah 21589, Saudi Arabia
[6] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Jeddah 21589, Saudi Arabia
[7] Minist Hlth, Prince Mohammed Bin Nasser Hosp, Jazan 82943, Saudi Arabia
[8] Minist Hlth, Eradah Hosp, Jazan 82943, Saudi Arabia
关键词
metabolomics; B-cell non-Hodgkin's lymphoma; biomarkers; metabolites; early diagnosis; therapeutic; GENOMIC URACIL; LARGE-SCALE; METABOLISM; SERUM; INHIBITION; MUTATIONS; EXPRESSION; LEUKEMIA; SURVIVAL; CHROMATOGRAPHY;
D O I
10.3390/diagnostics13050861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin's lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin's lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called "metabolomics." A patient's phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin's lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin's lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin's lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Characterization of unique B-cell populations in the circulation of people living with HIV prior to non-Hodgkin lymphoma diagnosis
    Martinez, Laura E.
    Comin-Anduix, Begona
    Guemes-Aragon, Miriam
    Ibarrondo, Javier
    Detels, Roger
    Mimiaga, Matthew J.
    Epeldegui, Marta
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma
    Civallero, Monica
    Cosenza, Maria
    Bari, Alessia
    Sacchi, Stefano
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (08) : 1029 - 1031
  • [23] Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma
    Hashmi, Hamza
    Hamadani, Mehdi
    Awan, Farrukh T.
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (15) : 1631 - 1634
  • [24] Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: a population-based study
    Wenshuai Zheng
    Bo Peng
    Huaxin Chen
    Shenyu Wang
    Lixun Guan
    Xiaoning Gao
    Annals of Hematology, 2025, 104 (5) : 2799 - 2811
  • [25] Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells
    Tamayo-Orbegozo, Estibaliz
    Amo, Laura
    Rinon, Marta
    Nieto, Naiara
    Amutio, Elena
    Maruri, Natalia
    Solaun, Miren
    Arrieta, Arantza
    Larrucea, Susana
    ONCOTARGET, 2017, 8 (59) : 99722 - 99739
  • [26] Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma
    Weiss, Jonathan M.
    Phillips, Tycel J.
    CANCERS, 2024, 16 (09)
  • [27] Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
    Russi, Sabino
    Sansonno, Loredana
    Sansonno, Domenico
    CURRENT DRUG TARGETS, 2017, 18 (07) : 766 - 771
  • [28] Increased frequency of circulating Th22 cells in patients with B-cell non-Hodgkin's lymphoma
    Lu, Ting
    Liu, Yan
    Yu, Shuang
    Yin, Congcong
    Li, Peng
    Ye, Jingjing
    Ma, Daoxin
    Ji, Chunyan
    ONCOTARGET, 2016, 7 (35) : 56574 - 56583
  • [29] Effect of body mass index on the prognosis of children and adolescents with high-grade mature B-cell non-Hodgkin lymphoma
    Zeng, Chenggong
    Wei, Zhiqing
    Huang, Junting
    Zhu, Jia
    Sun, Feifei
    Wang, Juan
    Lu, Suying
    Zhang, Yizhuo
    Sun, Xiaofei
    Zhen, Zijun
    CANCER, 2024, 130 (23) : 4109 - 4117
  • [30] Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England
    Miret, Montserrat
    Anderson, Amanda
    Hindocha, Pooja
    Cirneanu, Lorena
    Lymperopoulou, Christina
    Markov, Emanuil
    Kizito, William
    Vegni, Ferdinando Emanuele
    LEUKEMIA RESEARCH, 2023, 127